

PRESS RELEASE

Solna, 23 September 2021

Positive results with Endocine™ and a vaccine candidate against COVID-19

The first preclinical study, where the adjuvant technology Endocine™ has been evaluated with a vaccine candidate against COVID-19, shows positive results.

In May 2021, Eurocine Vaccine signed an evaluation agreement with an innovative North American company with the ambition to evaluate Endocine™ along with their vaccine candidate against COVID-19.

The first study in a mouse model indicates positive results with our adjuvant Endocine™, where antibodies of both type IgA and IgG could be detected, as well as T cell immunity.

The North American company now intends to proceed with additional studies where Eurocine Vaccines will deliver Endocine™ and assist with knowledge and experience within the area.

Read more about our adjuvant:

<https://www.eurocine-vaccines.com/the-portfolio/>

Contact

If you have any questions, please contact CEO Hans Arwidsson

hans.arwidsson@eurocine-vaccines.com

+46 70 634 0171

About Eurocine Vaccines

Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.

Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with big future leverage. These candidates are later licensed to partners for commercialization.

The company is in the possession of its technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.

Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden, and has attracted several internationally merited vaccine specialists to its board.